Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases

Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Treatment Name</td>
<td>Mesenchymal Stem Cell (MSC) Therapy</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mesenchymal Stromal Cells</td>
</tr>
<tr>
<td class="label">Target Indications</td>
<td>Parkinson's Disease, Alzheimer's Disease, ALS, Multiple System Atrophy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Immunomodulation, neurotrophic factor secretion, mitochondrial transfer</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Intravenous, intrathecal, stereotactic injection</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1/2 clinical trials</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Minimally invasive, systemic effect</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF delivery</td>
</tr>
<tr>
<td class="label">Stereotactic</td>
<td>Precise brain targeting</td>
</tr>
<tr>
<td class="label">Intra-arterial</td>
<td>High CNS exposure</td>
</tr>
</table>

Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Treatment Name</td>
<td>Mesenchymal Stem Cell (MSC) Therapy</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mesenchymal Stromal Cells</td>
</tr>
<tr>
<td class="label">Target Indications</td>
<td>Parkinson's Disease, Alzheimer's Disease, ALS, Multiple System Atrophy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Immunomodulation, neurotrophic factor secretion, mitochondrial transfer</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Intravenous, intrathecal, stereotactic injection</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1/2 clinical trials</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Minimally invasive, systemic effect</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF delivery</td>
</tr>
<tr>
<td class="label">Stereotactic</td>
<td>Precise brain targeting</td>
</tr>
<tr>
<td class="label">Intra-arterial</td>
<td>High CNS exposure</td>
</tr>
</table>

Mesenchymal Stem Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mesenchymal stem cells (MSCs) are adult stem cells with powerful immunomodulatory and neurotrophic properties that make them attractive candidates for cell therapy in neurodegenerative diseases.

Mechanism of Action

MSCs exert therapeutic effects through multiple mechanisms:

Immunomodulation

• T-cell regulation: Suppress pro-inflammatory T-cell responses
• Microglial modulation: Shift [microglia](/entities/microglia) from M1 (pro-inflammatory) to M2 (protective) phenotype
• Cytokine modulation: Reduce pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ)

Neurotrophic Support

• BDNF secretion: Brain-derived neurotrophic factor promotes neuronal survival
• GDNF secretion: Glial cell line-derived neurotrophic factor supports dopaminergic [neurons](/entities/neurons)
• VEGF secretion: Vascular endothelial growth factor promotes neurovascular health

Mitochondrial Transfer

• Tunneling nanotubes: MSCs can transfer mitochondria to damaged neurons
• Metabolic rescue: Restore ATP levels in stressed neurons
• Bioenergetic support: Improve neuronal metabolism

Tissue Repair

• Secretome effects: MSC-derived [exosomes](/entities/exosomes) carry therapeutic cargo
• Anti-apoptotic effects: Reduce neuronal death
• Synaptic protection: Preserve synaptic connections

Clinical Development

Parkinson's Disease

• Phase 1/2 Trials (NCT00911326, NCT01827180): MSC transplantation
• Results: Safe, well-tolerated; improved motor scores in some patients
• Reference: PMID:24721108, PMID:28182767
• ongoing Phase 2: Optimizing cell dose and delivery

Alzheimer's Disease

• Phase 1 Trials: MSC infusion in AD patients
• Results: Safe; trends toward cognitive stabilization
• Reference: PMID:26238515
• Phase 2 Trials: Ongoing in mild-to-moderate AD

Amyotrophic Lateral Sclerosis

• Phase 1/2 Trials (NCT01348451): MSC-NT3 delivery
• Results: Slowed disease progression in treatment arm
• Reference: PMID:24740773
• NurOwn®: Autologous MSC therapy (BrainStorm Cell Therapeutics)
• Phase 3 completed: Mixed results

Multiple System Atrophy

• Phase 1 Trial: MSC transplantation
• Results: Safe; potential neuroprotective effects

Therapeutic Implications

Potential Benefits

• Disease modification: Targets multiple pathogenic pathways
• Autologous options: Patient's own cells reduce rejection risk
• Multiple administrations: Repeat dosing possible
• Off-the-shelf allogeneic: Universal donor cells available

Challenges

• Survival in CNS: Limited engraftment and survival
• Optimal delivery: Best route still being determined
• Variability: MSC preparations vary between patients/sources
• Cost: Cell therapy is expensive
• Long-term effects: Unknown durability of benefit

Delivery Routes

MSC Sources

• Bone marrow: Traditional source, well-characterized
• Umbilical cord: Younger cells, higher proliferative capacity
• Adipose tissue: Abundant, easier collection
• Dental pulp: Easy access, neural crest origin

Combination Therapies

MSC therapy may be combined with:

• Growth factors: GDNF, BDNF delivery
• Gene therapy: Ex vivo genetic modification
• Small molecules: Immunomodulatory drugs
• Physical therapy: Rehabilitation to enhance integration

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease) - Target disease
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Target disease
• [ALS](/diseases/amyotrophic-lateral-sclerosis) - Target disease
• [GDNF](/proteins/gdnf-protein) - Neurotrophic factor
• [Cell Therapy for Neurodegeneration](/therapeutics/cell-therapy-neurodegeneration) - Related treatment
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) - Target pathway

Background

The study of Mesenchymal Stem Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

• [ClinicalTrials.gov - MSC Neurodegeneration](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=Mesenchymal+Stem+Cell)
• [ISCT - Mesenchymal Stem Cells](https://www.isctglobal.org)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;